Navigation Links
Swiss study suggests surgery may offer best chance of long-term prostate cancer survival
Date:10/8/2007

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Prostate cancer treatments are still being debated because they have not yet been compared in a randomized trial, in which men would be randomly assigned to one treatment or another, according to background information in the article. Therefore, treatment choice is strongly influenced by patient and physician personal preferences and experiences, the authors write.

Arnaud Merglen, M.D., of Geneva University, Switzerland, and colleagues used data from the Geneva Cancer Registry to assess all 844 patients diagnosed with localized (not yet spread) prostate cancer in Geneva between 1989 and 1998. Of those men, 158 received prostatectomy, or surgery to remove all or part of the prostate; 205 had radiation treatment (radiotherapy); 378 chose watchful waiting, which entails active follow-up and treatment if the disease progresses; 72 underwent hormone therapy; and 31 had another type of therapy.

The average follow-up was 6.7 years (range zero to 15.8 years), and 47 patients (5.6 percent) left Geneva and the study before the study concluded.

At 10 years, patients treated with radiotherapy or watchful waiting had a significantly increased risk of death from prostate cancer compared with patients who underwent prostatectomy, the authors write. Ten-year survival rates from prostate cancer were 83 percent for prostatectomy, 75 percent for radiotherapy, 72 percent for watchful waiting, 41 percent for hormone therapy and 71 percent for other treatment. The increased mortality associated with radiotherapy and watchful waiting was primarily observed in patients younger than 70 years and in patients with poorly differentiated tumors, or tumors that have certain cellular characteristics and are more likely to spread aggressively.

Until clinical trials provide conclusive evidence, physicians and patients should be informed of these results and their limitations, the authors conclude. '/>"/>

Contact: Christine Bouchardy
christine.bouchardymagnin@imsp.unige.ch
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Swiss Researchers Isolate Hair-Raising Stem Cells
2. Euthanasia To Be Permitted In Swiss Hospital
3. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
4. Rural Canadians travel far for specialists: study
5. A new study surpasses Gene Therapy Hurdle
6. Tomato Sauce reduces Cancer Risk- Study
7. A question on study of Adult Stem Cell
8. Study on obesity and heart failure
9. National Lung Study in the process
10. Marijuana gateway theory strengthened by study of twins
11. Old theory of adaptation confirmed by new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... ... are thinking of a visit to San Francisco , fall is a great time ... visit. , Business Architecture Associates is pleased to offer 5 days of training courses, available ... package for individuals, and as 4-½ day corporate package for up to 3 employees with ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included ... and health systems in the nation and help their organizations navigate the challenges ... and been instrumental in developing successful hospital and health system strategy. , Becker's ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... sleep diagnostics sensors, announced today it had completed the first phase of building ... of domestic and rest of world (ROW) authorized dealers specializing in polysomnography accessories. ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... N.Y. (PRWEB) , ... May 23, 2017 , ... New ... Public Health Crisis Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on ... Staunton Foundation for the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)... and SAN DIEGO , May 4, ... (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP Medical ... medical devices, today announced the launch of a new ... OfficeSPEC and ER-SPEC vaginal specula. Already ... extra-small and extra-large sizes makes OBP Medical,s line of ...
Breaking Medicine Technology: